540 related articles for article (PubMed ID: 8949927)
1. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
2. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
[TBL] [Abstract][Full Text] [Related]
3. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Brannan T; Prikhojan A; Martínez-Tica J; Yahr MD
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):79-89. PubMed ID: 9620056
[TBL] [Abstract][Full Text] [Related]
4. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
Sivam SP
Neuropeptides; 1993 Jul; 25(1):35-45. PubMed ID: 7692341
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
6. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Wachtel SR; Abercrombie ED
J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
[TBL] [Abstract][Full Text] [Related]
7. Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.
Lakshmana MK; Rao BS; Dhingra NK; Ravikumar R; Govindaiah ; Sudha S; Meti BL; Raju TR
Neurochem Res; 1998 Aug; 23(8):1031-7. PubMed ID: 9704592
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
9. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
Rothblat DS; Schneider JS
Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
[TBL] [Abstract][Full Text] [Related]
10. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
11. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Ilani T; Lamensdorf I; Finberg JP
Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
[TBL] [Abstract][Full Text] [Related]
12. Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (-)-deprenyl.
Hársing LG; Vizi ES
Br J Pharmacol; 1984 Nov; 83(3):741-9. PubMed ID: 6439273
[TBL] [Abstract][Full Text] [Related]
13. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Waldmeier PC; Delini-Stula A; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
[TBL] [Abstract][Full Text] [Related]
14. Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa.
Fredriksson A; Palomo T; Archer T
Behav Pharmacol; 2000 Nov; 11(7-8):571-81. PubMed ID: 11198128
[TBL] [Abstract][Full Text] [Related]
15. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.
Azzaro AJ; King J; Kotzuk J; Schoepp DD; Frost J; Schochet S
J Neurochem; 1985 Sep; 45(3):949-56. PubMed ID: 3928811
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
17. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
[TBL] [Abstract][Full Text] [Related]
18. Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum.
Adachi K; Miwa H; Kusumoto H; Shimazu S; Kondo T
J Pharmacol Sci; 2006 Aug; 101(4):286-92. PubMed ID: 16891770
[TBL] [Abstract][Full Text] [Related]
19. Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties).
Gesi M; Santinami A; Ruffoli R; Conti G; Fornai F
Pharmacol Toxicol; 2001 Nov; 89(5):217-24. PubMed ID: 11881974
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
Paterson IA; Juorio AV; Berry MD; Zhu MY
J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]